

REMARKS/ARGUMENTS

Claims 1–20 are pending in the application, and all of those claims have been rejected. A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) is used to overcome the rejection.

I. Specification Objection

The disclosure was objected to on the basis that the phrase “now U.S. Patent No. 6,750,661 B2 issued on June 15, 2004” must be added. Appropriate correction has been made, as is reflected in the Amendment to the Specification on page 2 of this paper.

II. Claim rejections under the judicially created doctrine of obviousness-type double patenting

Claims 1–20 were rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1–66 of U.S. Patent No. 6,750,661 B2. A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) accompanies this Office action response. As indicated in the disclaimer, U.S. Patent No. 6,750,661 B2 is commonly owned with this application.

Conclusion

For the foregoing reasons, Applicants believe all the pending claims are in condition for allowance and should be passed to issue. If the Examiner feels that a telephone conference would in any way expedite the prosecution of the application, please do not hesitate to call the undersigned attorney.

Respectfully submitted,



Ann C. Petersen
Reg. No. 55,536

CALIPER LIFE SCIENCES, INC.
605 Fairchild Drive
Mountain View, CA 94043
Direct: 650-623-0667
Fax: 650-623-0504
ann.petersen@caliperLS.com

CERTIFICATE OF TRANSMISSION OR MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 3, 2005 by Michael Moores.

Signed: 